Compass Therapeutics Inc.

NASDAQ CMPX

Data sourced from

and

Download Data

Compass Therapeutics Inc. Short-Term Debt to Total Assets Ratio 5 year CAGR for the year ending December 31, 2023: -33.13%

Compass Therapeutics Inc. Short-Term Debt to Total Assets Ratio 5 year CAGR is -33.13% for the year ending December 31, 2023. The short-term debt to total assets ratio measures the proportion of short-term debt to total assets of a company. It is calculated by dividing the short-term debt by the total assets. This ratio indicates the extent to which short-term debt contributes to the company's total asset structure. A higher ratio suggests a higher level of short-term debt relative to total assets. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Compass Therapeutics Inc. Short-Term Debt to Total Assets Ratio for the year ending December 31, 2022 was 0.01, a -14.57% change year over year.
Compass Therapeutics Inc. Short-Term Debt to Total Assets Ratio for the year ending December 31, 2021 was 0.01, a -95.53% change year over year.
Compass Therapeutics Inc. Short-Term Debt to Total Assets Ratio for the year ending December 31, 2020 was 0.14, a -21.63% change year over year.
Compass Therapeutics Inc. Short-Term Debt to Total Assets Ratio for the year ending December 31, 2019 was 0.18, a 221.61% change year over year.

NASDAQ: CMPX

Compass Therapeutics Inc.

CEO	Dr. Thomas J. Schuetz M.D., Ph.D.
IPO Date	April 5, 2021
Location	United States
Headquarters	80 Guest Street, Boston, MA, United States, 02135
Employees	32
Sector	Healthcare
Industry	Biotechnology

Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Key trends